Workflow
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
PRMEprime medicine(PRME) InvestorPlace·2024-03-01 19:00

The U.S. spends approximately 450billioneveryyeartreatingrarediseases.InvestingguruCathieWoodsaysmanagingpatientsafflictedwiththeseillnessescouldcost450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost 20 trillion over their lifetime. Curing these diseases would be invaluable.The likelihood of that happening is something one can only dream of today. Yet based on research from Wood’s Ark Invest, the companies pursuing these treatments could see their enterprise value race higher by a 28% compounded annual growth rate. That means by the en ...